Ozmosi

Indication-scoped drug-development intelligence built on a cross-referenced trial/drug/disease graph: more than 800,000 trials, 35,000 drugs and 4,000 diseases linked so programmes can be compared across indications. The thematic obesity cut holds 150-plus active programmes from preclinical to Phase 3, each classified by mechanism of action (incretin single/dual/tri agonists, amylin receptor agonists, INHBE and ALK7 RNAi, muscle-preservation, CB1 antagonists, rare-obesity indications), sponsor, asset name, formulation route, trial programme family (e.g. TRIUMPH, ACCOMPLISH, MARITIME), pivotal endpoints, quantitative efficacy readouts (28.3% mean body-weight loss at 80 weeks; 30.3% at 104 weeks in an extension cohort), enrolment and phase, plus regulatory-event dating (FDA approval 1 April 2026 for orforglipron, CagriSema under FDA review, planned Q1 2027 retatrutide submission).

Open buyer room →

Sample

Brickroad customers

Sample this dataset before you buy it.

Your sourcing agent asks Ozmosi and files the sample in your catalog — private to you.

Start 7-day trialNothing is charged until the trial ends.

Coverage

Universe, instruments and categories.

Industry: PharmaceuticalsHealth Care Technology
Instruments: equities
Categories

Dataset card

Type: not stated
Format: Structured relational records across three linked entity types (trials, drugs, diseases) surfaced through a subscription web intelligence platform and long-form thematic pipeline analyses with sortable tables; no public API, bulk export or file delivery is documented on the product page, so machine-readable delivery would need to be scoped with the vendor
Volume: Platform-wide: more than 800,000 trial records, 35,000 drug entities and 4,000 disease entities, cross-linked. Thematic obesity cut: 150-plus active programmes with mechanism, sponsor, programme-family, endpoint and efficacy-benchmark attributes. Implied density is high — three joined entity types with per-trial attributes rather than a single flat table — though per-record field counts and refresh cadence are not published
Users: N/A at platform level — subscription intelligence platform sold to pharma and investor teams with no published seat or customer count; a 10-person company suggests a client base in the tens to low hundreds of enterprise accounts
History: not stated
Update frequency: not stated
Growth: Active — the obesity pipeline analysis carries a 2026 as-of date and incorporates events from the current year (April 2026 approval, trials first dosed mid-2026, CagriSema under review), and the platform is presented as continuously tracked rather than a point-in-time report
Launched: ~2015-2018 — the corporate registration identifier on record dates to 2015, and the platform's breadth (800,000-plus trials) implies several years of accumulation before publication; no dated product launch is announced on the site
Delivery: not stated
Entity mapping: not stated
Sample: not stated
Point-in-time: not stated
Licence: not stated

supplier index read from their site